Evaxion Biotech A/S (NASDAQ:EVAX) inked an option and licensing deal with Merck & Co., Inc (NYSE:MRK) for two preclinical vaccine candidates.
Evaxion also granted Merck an option to license preclinical vaccine candidates EVX-B2 and EVX-B3.
EVX-B2 is a protein-based candidate for Gonorrhea, and EVX-B3 targets an undisclosed infectious agent.
Also Read: Why Is Cancer Therapy Focused Evaxion Biotech Stock Trading Higher Today?
Evaxion will receive an upfront payment of $3.2 million ...